BioCentury | Jan 8, 2021
Management Tracks

Moderna hires chief commercial officer as it ramps up COVID vaccine rollout; plus MorphoSys, Silence, Verastem, Viking, Destiny and Allen Institute

...who succeeds Rob Quinn, was CFO and COO at Vyome Therapeutics Inc.Metabolic and endocrine disorders company Viking...
...time he will join the board and become president-emeritus. BC Staff Moderna Inc. MorphoSys AG Allen Institute Silence Therapeutics plc Verastem Inc. Viking...
BioCentury | Jan 8, 2021
Finance

Crossovers back Affinivax in $236M round as more pipeline vaccines move toward clinic

...Perceptive Advisors, EcoR1 Capital, Citadel's Surveyor Capital and Logos Capital. Joining them were existing investors Viking...
BioCentury | Dec 12, 2020
Finance

RayzeBio gets unexpected lift from broad investor appetite for targeted radiotherapies

...by Venrock Healthcare Capital Partners (VHCP) and brought in new investors OrbiMed Advisers, Redmile Group, Viking...
BioCentury | Nov 19, 2020
Finance

Nov. 18 Quick Takes: Venture rounds for Elevation, Pharvaris as Kodiak follow-on brings in $560M; plus AbCellera takes out Trianni for $90M and more

...closes $80M series CPharvaris GmbH raised $80 million in a series C round led by Viking...
BioCentury | Nov 19, 2020
Finance

Seed financing in hand, VastBiome mines the genes of gut microbes

...therapies and biomarkers.Co-founder and CEO Kareem Barghouti said the seed round, which was co-led by Viking...
BioCentury | Nov 5, 2020
Deals

Merck adds ROR1 to its pipeline, rewards VelosBio’s investors with $2.8B takeout

...Capital Management, Foresite Capital, Janus Henderson Investors, Logos Capital, OrbiMed Advisors, T. Rowe Price, Venrock, Viking...
BioCentury | Oct 29, 2020
Finance

Perceptive-backed in-licensing play LianBio to cast a wide net with $310M crossover round

...Price Associates, Tybourne Capital Management, Vida Ventures, Viking...
BioCentury | Oct 7, 2020
Product Development

Oct. 6 Quick Takes: BARDA whistleblower quits NIH; plus COVID-19 updates from Vir-GSK, BioNTech, Pfizer, $115M B round for Talaris and more

...with centralized services for collection, receipt, storage, protection, processing, tracking, retrieval, packaging and distribution.  Surveyor, Viking...
...Inc. raised $115 million in a series B round co-led by Citadel’s Surveyor Capital and Viking...
BioCentury | Aug 3, 2020
Finance

After raising crossover-heavy $70M round, p53 play PMV likely one of the next preclinical IPOs

...Co. The existing investors joining OrbiMed is continuing to back the company are Nextech Invest, Viking...
BioCentury | Jul 31, 2020
Distillery Therapeutics

Targeting the metabolic enzyme DGAT1 to treat glioblastoma

...a DGAT1 inhibitor, in Phase I testing for metabolic disorders. Ligand Pharmaceuticals Inc. (NASDAQ:LGND) and Viking...
Items per page:
1 - 10 of 147
BioCentury | Jan 8, 2021
Management Tracks

Moderna hires chief commercial officer as it ramps up COVID vaccine rollout; plus MorphoSys, Silence, Verastem, Viking, Destiny and Allen Institute

...who succeeds Rob Quinn, was CFO and COO at Vyome Therapeutics Inc.Metabolic and endocrine disorders company Viking...
...time he will join the board and become president-emeritus. BC Staff Moderna Inc. MorphoSys AG Allen Institute Silence Therapeutics plc Verastem Inc. Viking...
BioCentury | Jan 8, 2021
Finance

Crossovers back Affinivax in $236M round as more pipeline vaccines move toward clinic

...Perceptive Advisors, EcoR1 Capital, Citadel's Surveyor Capital and Logos Capital. Joining them were existing investors Viking...
BioCentury | Dec 12, 2020
Finance

RayzeBio gets unexpected lift from broad investor appetite for targeted radiotherapies

...by Venrock Healthcare Capital Partners (VHCP) and brought in new investors OrbiMed Advisers, Redmile Group, Viking...
BioCentury | Nov 19, 2020
Finance

Nov. 18 Quick Takes: Venture rounds for Elevation, Pharvaris as Kodiak follow-on brings in $560M; plus AbCellera takes out Trianni for $90M and more

...closes $80M series CPharvaris GmbH raised $80 million in a series C round led by Viking...
BioCentury | Nov 19, 2020
Finance

Seed financing in hand, VastBiome mines the genes of gut microbes

...therapies and biomarkers.Co-founder and CEO Kareem Barghouti said the seed round, which was co-led by Viking...
BioCentury | Nov 5, 2020
Deals

Merck adds ROR1 to its pipeline, rewards VelosBio’s investors with $2.8B takeout

...Capital Management, Foresite Capital, Janus Henderson Investors, Logos Capital, OrbiMed Advisors, T. Rowe Price, Venrock, Viking...
BioCentury | Oct 29, 2020
Finance

Perceptive-backed in-licensing play LianBio to cast a wide net with $310M crossover round

...Price Associates, Tybourne Capital Management, Vida Ventures, Viking...
BioCentury | Oct 7, 2020
Product Development

Oct. 6 Quick Takes: BARDA whistleblower quits NIH; plus COVID-19 updates from Vir-GSK, BioNTech, Pfizer, $115M B round for Talaris and more

...with centralized services for collection, receipt, storage, protection, processing, tracking, retrieval, packaging and distribution.  Surveyor, Viking...
...Inc. raised $115 million in a series B round co-led by Citadel’s Surveyor Capital and Viking...
BioCentury | Aug 3, 2020
Finance

After raising crossover-heavy $70M round, p53 play PMV likely one of the next preclinical IPOs

...Co. The existing investors joining OrbiMed is continuing to back the company are Nextech Invest, Viking...
BioCentury | Jul 31, 2020
Distillery Therapeutics

Targeting the metabolic enzyme DGAT1 to treat glioblastoma

...a DGAT1 inhibitor, in Phase I testing for metabolic disorders. Ligand Pharmaceuticals Inc. (NASDAQ:LGND) and Viking...
Items per page:
1 - 10 of 147